CL2014003167A1 - Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6. - Google Patents
Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6.Info
- Publication number
- CL2014003167A1 CL2014003167A1 CL2014003167A CL2014003167A CL2014003167A1 CL 2014003167 A1 CL2014003167 A1 CL 2014003167A1 CL 2014003167 A CL2014003167 A CL 2014003167A CL 2014003167 A CL2014003167 A CL 2014003167A CL 2014003167 A1 CL2014003167 A1 CL 2014003167A1
- Authority
- CL
- Chile
- Prior art keywords
- inteleukin
- vector
- nucleic acid
- pharmaceutical composition
- host cell
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650883P | 2012-05-23 | 2012-05-23 | |
US201261720102P | 2012-10-30 | 2012-10-30 | |
PCT/IB2012/056424 WO2013175276A1 (en) | 2012-05-23 | 2012-11-14 | Il-6 binding molecules |
PCT/IB2013/054271 WO2013175427A1 (en) | 2012-05-23 | 2013-05-23 | Il-6 binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014003167A1 true CL2014003167A1 (es) | 2015-06-12 |
Family
ID=47559582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014003167A CL2014003167A1 (es) | 2012-05-23 | 2014-11-21 | Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6. |
Country Status (17)
Country | Link |
---|---|
US (4) | US10183995B2 (es) |
EP (1) | EP2852616A1 (es) |
JP (1) | JP6410712B2 (es) |
KR (1) | KR20150063311A (es) |
CN (1) | CN103601806B (es) |
AU (1) | AU2013264779B2 (es) |
BR (1) | BR112014029219B1 (es) |
CA (1) | CA2871148C (es) |
CL (1) | CL2014003167A1 (es) |
CO (1) | CO7240362A2 (es) |
EC (1) | ECSP14029713A (es) |
IL (1) | IL235134B (es) |
MX (1) | MX360163B (es) |
NZ (1) | NZ701370A (es) |
PE (1) | PE20150335A1 (es) |
RU (1) | RU2676078C2 (es) |
WO (2) | WO2013175276A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113117074A (zh) | 2015-07-31 | 2021-07-16 | 米迪缪尼有限公司 | 用于治疗海帕西啶介导的病症的方法 |
CN105194655A (zh) * | 2015-10-21 | 2015-12-30 | 胶州市人民中医医院 | 一种新生儿细菌感染性脑炎的治疗方法 |
SG10201912128SA (en) | 2017-02-01 | 2020-02-27 | Univ Yale | Treatment of diuretic resistance |
BR112020013519A2 (pt) | 2018-01-05 | 2020-12-01 | Corvidia Therapeutics, Inc | método para tratamento de uma inflamação. |
CN111153998B (zh) * | 2020-01-16 | 2022-06-24 | 佛山汉腾生物科技有限公司 | 抗ctla-4纳米抗体及其应用 |
CN115443147A (zh) * | 2020-04-23 | 2022-12-06 | 伊莱利利公司 | 抗体的皮下吸收和生物利用度 |
CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
WO2023229891A1 (en) * | 2022-05-25 | 2023-11-30 | Ayuvis Research, Inc. | Novel immunodulating small molecules |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
DK0574395T3 (da) | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
DK1562968T3 (da) * | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
EP1562972B1 (en) | 2002-10-15 | 2010-09-08 | Facet Biotech Corporation | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション,インコーポレイテッド | Fc領域変異体 |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2008500064A (ja) | 2004-05-21 | 2008-01-10 | ザ ユーエービー リサーチ ファウンデーション | 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用 |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
PA8672101A1 (es) * | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
ES2523666T3 (es) | 2005-05-31 | 2014-11-28 | Board Of Regents, The University Of Texas System | Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos |
UA96141C2 (ru) | 2005-12-09 | 2011-10-10 | Юсиби Фарма, С.А. | Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 |
AR057227A1 (es) * | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
US20110059101A9 (en) * | 2006-03-13 | 2011-03-10 | Ablynx N.V. | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
BRPI0715115A2 (pt) * | 2006-08-03 | 2013-06-04 | Vaccinex Inc | anticorpo monoclonal isolado, molÉcula de Ácido nucleico isolada, vetor de expressço, cÉlula hospedeira, mÉtodos para tratar uma doenÇa, e para produzir um anticorpo monoclonal isolado, uso do anticorpo monoclonal isolado, e, composiÇço farmacÊutica |
TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
TWI561530B (en) | 2007-05-21 | 2016-12-11 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
KR20110094307A (ko) * | 2008-11-13 | 2011-08-23 | 펨타 파마슈티컬스, 인크. | 인간화된 항-il-6 항체 |
MX337590B (es) * | 2009-01-29 | 2016-03-11 | Medimmune Llc | Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias. |
US20110086770A1 (en) | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Combinatorial Libraries Based on C-type Lectin-like Domain |
-
2012
- 2012-11-14 WO PCT/IB2012/056424 patent/WO2013175276A1/en active Application Filing
-
2013
- 2013-05-23 WO PCT/IB2013/054271 patent/WO2013175427A1/en active Application Filing
- 2013-05-23 NZ NZ701370A patent/NZ701370A/en unknown
- 2013-05-23 CA CA2871148A patent/CA2871148C/en active Active
- 2013-05-23 RU RU2014152006A patent/RU2676078C2/ru active
- 2013-05-23 US US14/403,135 patent/US10183995B2/en active Active
- 2013-05-23 CN CN201310193693.6A patent/CN103601806B/zh active Active
- 2013-05-23 JP JP2015513338A patent/JP6410712B2/ja active Active
- 2013-05-23 KR KR1020147031922A patent/KR20150063311A/ko not_active Application Discontinuation
- 2013-05-23 AU AU2013264779A patent/AU2013264779B2/en active Active
- 2013-05-23 BR BR112014029219-1A patent/BR112014029219B1/pt active IP Right Grant
- 2013-05-23 MX MX2014014218A patent/MX360163B/es active IP Right Grant
- 2013-05-23 EP EP13734185.5A patent/EP2852616A1/en not_active Withdrawn
- 2013-05-23 PE PE2014001913A patent/PE20150335A1/es not_active Application Discontinuation
-
2014
- 2014-10-19 IL IL235134A patent/IL235134B/en active IP Right Grant
- 2014-11-21 CL CL2014003167A patent/CL2014003167A1/es unknown
- 2014-11-24 CO CO14258229A patent/CO7240362A2/es unknown
- 2014-12-03 EC ECIEPI201429713A patent/ECSP14029713A/es unknown
-
2019
- 2019-01-03 US US16/239,321 patent/US11117959B2/en active Active
-
2021
- 2021-08-10 US US17/398,080 patent/US11827701B2/en active Active
-
2023
- 2023-10-23 US US18/492,526 patent/US20240158492A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20150335A1 (es) | 2015-03-20 |
MX360163B (es) | 2018-10-09 |
US10183995B2 (en) | 2019-01-22 |
RU2014152006A (ru) | 2016-07-20 |
US11117959B2 (en) | 2021-09-14 |
WO2013175276A1 (en) | 2013-11-28 |
CA2871148C (en) | 2020-07-14 |
CA2871148A1 (en) | 2013-11-28 |
US20150140011A1 (en) | 2015-05-21 |
KR20150063311A (ko) | 2015-06-09 |
BR112014029219B1 (pt) | 2022-04-19 |
JP6410712B2 (ja) | 2018-10-24 |
CN103601806A (zh) | 2014-02-26 |
AU2013264779A1 (en) | 2014-10-30 |
ECSP14029713A (es) | 2015-09-30 |
CO7240362A2 (es) | 2015-04-17 |
IL235134A0 (en) | 2014-12-31 |
JP2015518857A (ja) | 2015-07-06 |
BR112014029219A2 (es) | 2017-08-15 |
US20240158492A1 (en) | 2024-05-16 |
EP2852616A1 (en) | 2015-04-01 |
CN103601806B (zh) | 2019-01-18 |
NZ701370A (en) | 2016-11-25 |
US20220073604A1 (en) | 2022-03-10 |
MX2014014218A (es) | 2015-11-23 |
WO2013175427A1 (en) | 2013-11-28 |
US11827701B2 (en) | 2023-11-28 |
AU2013264779B2 (en) | 2018-03-22 |
BR112014029219A8 (pt) | 2019-05-14 |
US20190233509A1 (en) | 2019-08-01 |
IL235134B (en) | 2019-12-31 |
RU2676078C2 (ru) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014003167A1 (es) | Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6. | |
CL2014000631A1 (es) | Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
FR23C1032I1 (fr) | Protéines de liaison à bcma (cd269/tnfrsf17) | |
CL2015000420A1 (es) | Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3. | |
CL2014001254A1 (es) | Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes. | |
CL2015000532A1 (es) | Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico. | |
CL2013000074A1 (es) | Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos. | |
CL2013001625A1 (es) | Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa. | |
CL2013000669A1 (es) | Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie. | |
CL2014003465A1 (es) | Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. | |
CL2016002340A1 (es) | Proteínas de unión al antígeno cd27l; ácido nucleico que la codifica; vector de expresión; célula huésped recombinante; composición que la comprende; su uso para tratar cáncer, trastornos autoinmunitarios o inflamatorios; y método para elaborar un conjugado anticuerpo cd27l-fármaco (divisional sol. n° 699-14). | |
EA201600338A1 (ru) | Биспецифическая связывающая молекула, связывающаяся с vegf и ang2 | |
BR112014000263A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica | |
CL2015000665A1 (es) | Compuesto análogo de glucagón útil para prevenir ganancia de peso o promover pérdida de peso; ácido nucleico que lo codifica; vector; célula huésped; kit; y procedimiento de producción. | |
CL2013003043A1 (es) | Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune. | |
CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
AR089528A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
CL2014001930A1 (es) | Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2). | |
BR112014026990A2 (pt) | anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia. | |
CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
BR112015029788A2 (pt) | hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo | |
BR112014011594A2 (pt) | anticorpos anti-il-36r | |
CL2013002828A1 (es) | Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
DK3578659T3 (da) | Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression |